PRESS CONTACT

Alexa Ball

Email me

Founded

2018

Location

Pasadena, California,

United States

OUR STORY

Fuzionaire Diagnostics (“Fuzionaire Dx”) is a radiopharmaceutical company. Our radiolableing platform unlocks the power of PET to help detect and treat any disease.

The barriers to better imaging are the result of basic limitations in chemistry. Leveraging a breakthrough in alkali metal catalysis, Fuzionaire Dx is radically improving the resolution, safety, use, and cost of PET imaging.

Our patented HetSiFA™ compositions, which are synthesized using our alkali metal catalysts, can bioconjugate to any disease-targeting ligand, often at record-breaking speed.

For the first time, it is now possible to rapidly produce a broad range of fluorine-18 radiopharmaceuticals based on a single disease-agnostic platform. Using our technology, researchers and clinicians can detect, localize, diagnose, and monitor more diseases, earlier, and with unprecedented precision. Pharmaceutical companies can improve their drug discovery process along virtually every phase of development.

Fuzionaire Dx was co-founded by a team including CEO Nick Slavin, Chief Science Officer Anton Toutov, PhD, and Nova Spivack, and is advised by leading researchers in molecular imaging and drug discovery.

For more, visit us at: www.fuzionairedx.com

OUR TEAM

Nick slavin

Nick Slavin

Co-Founder and CEO

Mr. Slavin is the founder of EES Ventures, a venture capital firm focusing on seed-stage technologies out of universities, and founder and chairman of the Slavin Family Foundation, which operates a fellowship supporting world-changing student entrepreneurs. He is also a co-founder with Mr. Spivack of the Arch Mission Foundation, a nonprofit creating multiple redundant repositories of human knowledge in space, which created the first permanent library in solar orbit in February 2018 as part of SpaceX’s Falcon Heavy test launch. Previously, Mr. Slavin spent seven years as a corporate attorney at Norton Rose Fulbright and Skadden Arps, at the time the #1 ranked corporate law firm by Corporate Board Member magazine for 13 consecutive years. Mr. Slavin is an advisor at the Texas Medical Center Innovation Institute and an investor in and advisor to a number of life science, medical device, energy, and digital technology companies. He holds a BA magna cum laude from Yale, where he graduated at 19, and a JD from Harvard Law School.

Anton toutov

Anton Toutov, PhD.

Co-Founder and CSO

Dr. Toutov holds a PhD in organic chemistry from Caltech in the laboratory of Nobel Laureate Robert H. Grubbs, where he held Dow-Resnick, NSERC, and Bristol-Myers Squibb fellowships. Dr. Toutov collectively has over 40 scholarly articles and patent grants and applications to his name spanning the fields of chemical synthesis, clean energy, and drug discovery. Among them is the discovery of a new form of catalysis, which was first published in Nature and was later presented to general audiences in the documentary film Element 19. He is the recipient of the 2016 Demetriades Caltech Thesis Prize, the 2015 Alfred Bader Award for Student Innovation (Sigma-Aldrich Corporation), the 2014 Dow Chemical Sustainability Challenge Grand Prize, and the 2014 Milliken & Co. “Deep Science” award, among others. Dr. Toutov also serves as senior technical advisor to the Gates Foundation-backed Medicines for All Institute, improving access to affordable, high-quality medicines. 

Nove spivack

Nova Spivack

Co-Founder

Mr. Spivack is a serial entrepreneur, technology futurist, and co-founder of the in house incubator of Stanford Research Institute (SRI) and Sarnoff Laboratories, which launched SIRI (acquired by Apple). He is the founder and CEO of the early stage science and technology incubator, Magical, and is co-founder and chairman of the Arch Mission Foundation. Previously, Mr. Spivack was CEO of Bottlenose, a leader in real-time data analytics. He founded Radar Networks in 2003, business incubator Lucid Ventures in 2001, and in 1994 he co-founded EarthWeb, Inc., one of the first web start-ups (record-breaking IPO in 1998) and spinout Dice.com (IPO in 2007). He is also a co-founder or early investor in The Daily Dot, Klout (acquired by Lithium), and a number of applied and life science companies including Space Adventures and Cambrian Genomics. Mr. Spivack is an inventor on nearly 100 granted and pending patents.